Number of voting rights as of April 30, 2024
May 02 2024 - 11:45AM
Number of voting rights as of April 30, 2024
Nicox SA Société anonyme
with a registered capital of € 50,299,694
Head Office: Sundesk Sophia Antipolis,
Emerald Square, rue Evariste Galois – 06410 BiotR.C.S. ANTIBES
403.942.642
On May 2nd, 2024,
MONTHLY PUBLICATION OF THE NUMBER OF
SHARES COMPOSING THE SHARE CAPITAL AND OF THE TOTAL NUMBER OF
VOTING RIGHTS
(Article 223-16 of the General Regulation
of the AMF)
Market: Euronext Growth Paris ISIN Code:
FR0013018124Website: www.nicox.com
|
|
As of April 30, 2024 |
|
Total number of shares composing the share capital |
50,299,694 |
|
Total theoretical number of voting rights (1) |
50,299,694 |
|
Total effective number of voting rights (2) |
49,988,627 |
(1) Theoretical voting
rights are calculated on the basis of all shares to which voting
rights are attached, including shares without voting rights, in
accordance with Article 223-11 of the AMF's General
Regulations.(2) Effective voting rights
correspond to the total number of voting rights exercisable at the
General Meeting. They are calculated on the basis of the total
number of voting rights attached to the total number of shares less
shares without voting rights.
|
About Nicox |
|
Nicox SA is an international ophthalmology company developing
innovative solutions to help maintain vision and improve ocular
health. Nicox’s lead program in clinical development is NCX 470, a
novel nitric oxide-donating bimatoprost eye drop, for lowering
intraocular pressure in patients with open-angle glaucoma or ocular
hypertension. Nicox generates revenue from VYZULTA® in glaucoma,
licensed exclusively worldwide to Bausch + Lomb, and ZERVIATE® in
allergic conjunctivitis, licensed in multiple geographies,
including to Harrow, Inc. in the U.S., and Ocumension Therapeutics
in the Chinese and in the majority of Southeast Asian markets.
Nicox, headquartered in Sophia Antipolis, France, is listed on
Euronext Growth Paris (Ticker symbol: ALCOX) and is part of the CAC
Healthcare index. For more information www.nicox.com |
|
Analyst coverage |
|
Bryan, Garnier & Co
Eric
Yoo Paris,
FranceH.C. Wainwright &
Co Yi
Chen New York,
U.S. |
|
|
The views expressed by analysts in their coverage of Nicox are
those of the author and do not reflect the views of Nicox.
Additionally, the information contained in their reports may not be
correct or current. Nicox disavows any obligation to correct or to
update the information contained in analyst reports. |
|
Contacts |
|
|
NicoxGavin SpencerChief Executive Officer+33 (0)4
97 24 53 00communications@nicox.com |
Media / Investors Sophie Baumont Cohesion Bureau
+33 6 27 74 74 49 sophie.baumont@cohesionbureau.com |
Nicox (TG:NXOA)
Historical Stock Chart
From Apr 2024 to May 2024
Nicox (TG:NXOA)
Historical Stock Chart
From May 2023 to May 2024
